title: [Immunomodulation therapy of breast carcinoma with levamisole].
abstract: The authors present results of modality and immunomodulating treatment of breast cancer. In the treatment they use levamizole (Decaris) which has useful properties, as compared with other immunomodulating drugs--accurate dosage, simple administration and good tolerance. In a group of 84 patients it was administered after operation after adjuvant chemotherapy with Cyclophosphamide in a total dose of 300 mg orally, making check-up examinations of leucocytes and thrombocytes. As to other laboratory parameters, the authors assessed transaminases, alkaline phosphate, immunoglobulin, T-lymphocytes and carcinoembryonic antigen. During the same period the survival of patients in this group was significantly higher, as compared with a group of patients formerly treated by adjuvant chemotherapy with Cyclophosphamide without levamizole. Comparison of the results with those of other authors indicates that it is correct to include immunomodulating treatment in comprehensive treatment of breast cancer.
authors.forename: F
authors.initials: F
authors.lastname: Veselý
authors.forename: A
authors.initials: A
authors.lastname: Pelikán
authors.forename: J
authors.initials: J
authors.lastname: Kodýdek
mesh_terms: D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008875:Middle Aged
chemical_list: D000276:Adjuvants, Immunologic; D007978:Levamisole
vernacular_title: Imunomodulacná terapia karcinómu prsníka levamizolom.